Clinical Trials Details

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Krascendo 2)

IRB Protocol Number

CO45042 KRAScendo2

Clinical Trial Categories

• Lung Cancer

Contact

Clinical Trials at 910-715-2200

How to Participate

Eligibility: Men and women 18+ years old, with diagnosis of advanced or metastatic non squamous Non-Small Cell Lung Cancer that is not eligible for curative surgery and/or definitive chemoradiotherapy, must have no prior systemic treatment for advanced or metastatic NSCLC, and must have KRAS G12C mutation.